Annual Information Update

FOR IMMEDIATE RELEASE

27 April 2012

SkyePharma PLC - Annual Information Update

In accordance with the requirements of the UK Listing Authority's Prospectus Rule 5.2, the following information and documents were published, or made available to the public, over the 12 months from 27 April 2011 to 26 April 2012 (inclusive) in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets. All of the information referred to in this update was up-to-date at the time of its publication but it is acknowledged that such disclosures may, at any time, become out of date due to changing circumstances.

1. Announcements via RNS

The following UK regulatory announcements have been made via RNS a Regulatory Information Service and can be obtained from the London Stock Exchange website at www.londonstockexchange.com or the Company's website at www.skyepharma.com

Date Announcement

26/04/11 Annual Information Update

12/05/11 Interim Management Statement

12/05/11 AGM Results

20/05/11 Director/PDMR Shareholding

06/06/11 Director/PDMR Shareholding

07/07/11 Director/PDMR Shareholding

28/07/11 Re Agreement

01/08/11 Re Alliance with the Aenova Group

01/08/11 Amendment to CRC Finance Facility

03/08/11 Notice of Results

04/08/11 Holding(s) in Company

08/08/11 Director/PDMR Shareholding

17/08/11 Re Agreement

18/08/11 Half Yearly Report

02/09/11 Update on Diabetes Product Candidate

07/09/11 Head of Sales and Business Development Appointed

07/09/11 Director/PDMR Shareholding

09/09/11 Holding(s) in Company

12/09/11 Holding(s) in Company

28/09/11 NDA Submission in US for Lodotra® in RA

11/10/11 Director/PDMR Shareholding

18/10/11 Update on Flutiform™ Europe

31/10/11 US FDA Approval for NDA of Exparel™

04/11/11 Director/PDMR Shareholding

14/11/11 Interim Management Statement

29/11/11 Regulatory Application

12/12/11 Director/PDMR Shareholding

12/12/11 Director Declaration

23/12/11 Product Update

10/01/12 Reorganisation of Swiss Operations

10/01/12 Director/PDMR Shareholding

31/01/12 Directorate Change

03/02/12 Director/PDMR Shareholding

12/03/12 Notice of Results

15/03/12 Director/PDMR Shareholding

22/03/12 Final Results

05/04/12 Director/PDMR Shareholding

13/04/12 Annual Financial Report

20/04/12 Exparel $10m Milestone Payment

20/04/12 Flutiform Positive Outcome

23/04/12 Holding(s) in Company

2. Documents filed at Companies House

All of the documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated. Copies of the documents filed with the Registrar of Companies can be obtained from Companies House (www.companieshouse.gov.uk) or companies House, Crown Way, Cardiff, CF14 3UZ.

Date of Filing Brief Description of document(s) filed

17/05/11 AA Annual Report and Accounts

17/05/11 RES09 Authority to Purchase Shares

17/05/11 RES10 Authorised Allotment of Shares

17/05/11 RES11 Disapplication of Pre-Emption Rights

17/05/11 RES13 Approval of General Meeting

04/01/12 CH01 Director's Change of Particulars (PWG)

04/01/12 CH01 Director's Change of Particulars (TW)

05/01/12 CH01 Director's Change of Particulars (AJNB)

05/01/12 CH01 Director's Change of Particulars (FCC)

05/01/12 CH01 Director's Change of Particulars (J-CT)

05/01/12 AR01 Annual Return

31/01/12 TM01 Termination of Director's Appointment

3. Documents published or sent to Shareholders and submitted to the UK Listing Authority and filed with the National Storage Mechanism and available for inspection from www.morningstar.co.uk/uk/NSM:

Date Document

12/05/11 Resolutions passed at AGM

18/08/11 Half Yearly Report 2011

12/04/12 Annual Report 2011

12/04/12 Notice of Annual General Meeting 2012

12/04/12 Form of Proxy

Copies of the above documents can be obtained from the Company Secretary at:

SkyePharma PLC

46-48 Grosvenor Gardens

London

SW1W 0EB

For further information please contact:

SkyePharma PLC

John Murphy (Company Secretary) +44 207 881 0524

Singer Capital Markets Limited

Shaun Dobson / Claes Spång +44 203 205 7500

FTI Consulting

Jonathan Birt /Sue Quigley +44 207 831 3113

About SkyePharma

Using its multiple drug delivery technologies and expertise, SkyePharma creates enhanced versions of pharmaceutical products. The Group has eleven approved products in the areas of oral and topical delivery as well as important license and revenue-generating arrangements in inhalation and injectable technologies. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.